文献速递糖尿病

Imeglimin单药治疗日本2型糖尿病患者的疗效与安全性:TIMES 1双盲随机安慰剂对照3期试验

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
PubMed 文献 · Diabetes Care · 2021-02-11

该研究为日本30个中心开展的双盲、随机、平行组、安慰剂对照3期试验,纳入饮食运动治疗后稳定≥12周且HbA1c 7.0-10.0%的日本2型糖尿病患者106例(Imeglimin 1000mg每日两次)和107例(安慰剂),治疗24周。主要终点为HbA1c自基线至第24周的变化,Imeglimin组较安慰剂组调整后平均差异为-0.87%(95%CI -1.04至-0.69 [-9.5 mmol/mol; 95%CI -11.4至-7.5]; P<0.0001)。

要点

  • Imeglimin 1000mg每日两次治疗24周显著降低HbA1c,较安慰剂调整后平均差异-0.87%。
  • Imeglimin组不良事件发生率44.3%,与安慰剂组44.9%相似。
  • Imeglimin可能成为日本2型糖尿病患者的潜在新治疗选择。

核心结论

  • 在日本2型糖尿病患者中,Imeglimin较安慰剂显著改善HbA1c,且安全性特征与安慰剂相似。

研究设计与样本

  • 双盲、随机、平行组、安慰剂对照3期试验,在日本30个中心开展。
  • 纳入年龄≥20岁、饮食运动治疗后稳定≥12周、HbA1c 7.0-10.0%(53-86 mmol/mol)的日本2型糖尿病患者。
  • 患者按1:1随机分配至口服Imeglimin 1000mg每日两次组(106例)或匹配安慰剂组(107例),治疗24周。
  • 研究者、参与者和申办方在整个试验期间保持盲态。

主要发现

  • 第24周HbA1c自基线变化较安慰剂的调整后平均差异为-0.87%(95%CI -1.04至-0.69 [-9.5 mmol/mol; 95%CI -11.4至-7.5]; P<0.0001)。

关键数值与推荐

  • 主要终点:第24周HbA1c自基线变化。
  • 关键次要终点:第24周应答者百分比(根据两种定义)。

临床怎么用

  • 对于饮食运动治疗后血糖控制不佳的日本2型糖尿病患者,Imeglimin单药治疗可显著降低HbA1c且安全性类似安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the efficacy and safety of imeglimin, the first in a new class of oral antidiabetic agent, in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, parallel-group, placebo-controlled phase 3 trial in 30 sites in Japan. Eligible participants were individuals aged ≥20 years with type 2 diabetes treated with diet and exercise, stable for ≥12 weeks prior to screening, and whose HbA1c was 7.0-10.0% (53-86 mmol/mol). Patients were randomly assigned (1:1) to either oral imeglimin (1,000 mg twice daily) or matched placebo for 24 weeks. Investigators, participants, and the sponsor of the study remained blinded throughout the trial. The primary end point was the change in mean HbA1c from baseline to week 24, and the key secondary end point was the percentage of responders (according to two definitions) at week 24. RESULTS: Between 26 December 2017 and 1 February 2019, 106 and 107 patients were randomly assigned to treatment with imeglimin and placebo, respectively. Compared with placebo, the adjusted mean difference in change from baseline HbA1c at week 24 was -0.87% (95% CI -1.04 to -0.69 [-9.5 mmol/mol; 95% CI -11.4 to -7.5]; P < 0.0001). Forty-seven (44.3%) patients reported ≥1 adverse event in the imeglimin group versus 48 adverse events (44.9%) in the placebo group. CONCLUSIONS: Imeglimin significantly improved HbA1c in Japanese patients with type 2 diabetes compared with placebo and had a similar safety profile to placebo. Imeglimin represents a potential new treatment option for this population.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dubourg J, Fouqueray P, Thang C, et al. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial. Diabetes Care. 2021. PMID: 33574125. doi:10.2337/dc20-0763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。